IDSA releases new treatment guidance for drug-resistant pathogens
The Infectious Diseases Society of America (IDSA) yesterday released new guidelines for the treatment of three common antibiotic-resistant pathogens.
The goal of the guidelines, the first in a series of narrowly focused guidance documents that IDSA will be publishing on multiple platforms, are to assist clinicians in selecting antibiotic therapy for extended-spectrum beta-lactamase–producing Enterobacterales (ESBL-E), carbapenem-resistant Enterobacterales (CRE), and Pseudomonas aeruginosa with difficult-to-treat resistance (DTR-P aeruginosa). The three pathogens have been designated as serious or urgent threats by the Centers for Disease Control and Prevention, cause a wide variety of infections, and have limited treatment options.
Created as an alternative to comprehensive clinical practice guidelines, which can take years to produce and publish, the guidance was developed by a panel of six infectious diseases specialists with expertise in antibiotic-resistant bacterial infections to address specific clinical questions about difficult-to-manage infections that are not covered by current guidelines, and is based on a review of the literature.
"Clinicians rely on evidence-based guidelines from other clinicians who have considered the literature and available data," panel co-chair Cornelius J. Clancy, MD, VA Pittsburgh Healthcare System's chief of infectious diseases and an associate professor of medicine and director of the XDR Pathogen Lab at the University of Pittsburgh, said in an IDSA press release. "This guidance provides clinicians with real-word recommendations on how to deal with real-world problems."
The guidance will be updated as new data emerge, and future iterations will address other resistant pathogens.
Sep 8 IDSA guidance
Sep 8 IDSA press release
Study: Discordant antibiotics fairly common for bloodstream infections
A study led by researchers with the National Institutes of Health found that nearly one in five patients with bloodstream infections in US hospitals received discordant antibiotic therapy, which was associated with antibiotic-resistant pathogens and increased mortality. The results appeared yesterday in The Lancet Infectious Diseases.
The retrospective cohort analysis of electronic health record (EHR) data from 131 US hospitals looked at all patients with suspected and subsequently confirmed bloodstream infections who were treated empirically with antibiotics from 2005 through 2014.
The researchers defined empiric antibiotic therapy as discordant if the bloodstream isolate from a patient did not display in-vitro susceptibility to any systemic antibiotic administered in the day of blood culture sampling. Using the EHR data, they estimated the prevalence of discordant antibiotic therapy, identified predictors of receiving discordant therapy, and calculated the adjusted odds ratio for the relationship between discordant therapy and in-hospital mortality.
Of the 21,608 patients who received empiric antibiotics on the first day of blood culture collection, 4,165 (19%) received discordant empiric antibiotic therapy based on retroactive assessment of final susceptibility results. Of those patients, 1,958 (49%) had antibiotic-resistant bloodstream isolates. Most patients who received discordant therapy had infections caused by resistant Enterobacterales or Staphylococcus aureus. Patients infected with antibiotic-resistant pathogens were nine times more likely to receive discordant empiric therapy than those with susceptible infections (adjusted odds ratio, 9.09; 95% confidence interval [CI], 7.68 to 10.76).
Discordant empiric therapy was independently associated with a significantly increased risk of mortality (adjusted odds ratio, 1.46; 95% CI, 1.28 to 1.66), which was unaffected by the presence or absence of resistance, sepsis, or septic shock.
The study also found that discordant empiric therapy was not significantly affected by hospital-level characteristics, a finding the authors say suggests that the problem is widespread, and that any efforts to optimize empiric prescribing would need to be implemented on a large scale.
"Such optimisation is likely to improve survival in all bacteraemic patients," they wrote. "Early identification of bloodstream pathogens, especially Enterobacterales and S aureus, and associated resistance profiles could improve outcomes in patients with bloodstream infections on a population level."
Sep 8 Lancet Infect Dis abstract